Evolution Biotech, Author at Evolution Biotechnologies
1
archive,author,author-leadbroker,author-1,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Japanese Patent Office announces its intention to grant Evolution  Biotechnologies Application No. 2018-525822, “Acaricidals” Bedford, UK, February 1st 2021 Evolution Biotechnologies (www.evolutionbiotech.com), the UK based company pioneering the use of biological control to benefit human health, today announced that it has been notified  by the Japan Patent Office of their intention to grant Patent Application No. 2018-525822,  “Acaricidals”, deriving from WO2017025732A1 “Acaricides”, This will provide broad  protection for both formulation and use of Evolution’s biological control technology for house  dust mites in the control of asthma and other allergic diseases. As a result of this award, Evolution will now have exclusive...

Evolution Biotechnologies announces presentation at Bioseed Investment Event, to be held virtually on 21 January 2021 Bedford, UK, January 9th, 2021 Evolution Biotechnologies (www.evolutionbiotech.com), the UK based company pioneering the use of biological control to benefit human health, today announced its intention to present at the OBN BioSeed Investment Event on 21st January 2021. CEO Dr. David Harper will present a summary of the company’s activities and the progression of its technology. About Evolution Biotechnologies: Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the...

Bedford, UK, July 20th 2020 Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports that it has completed the registration process and has been listed on Oxford Business Network’s OBN Ventures Investment Platform at https://obn.envestry.com/. Dr. David Harper, CEO of Evolution, said: “this is an important step forward in today’s difficult market, and we look forward to working with OBN Ventures to present this opportunity to a new group of investors”. About OBN Ventures: OBN Ventures Ltd (OBNV) is a wholly owned subsidiary of OBN (UK) Ltd, and offers a sophisticated FCA-approved on-line investment platform...

Bedford, UK, June 8th 2020 Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports that it has received advance assurance of eligibility for the Enterprise Investment Scheme (EIS) status from the tax authorities in the UK for its next investment round. The EIS scheme provides additional tax relief for UK-based investors, and Evolution has secured EIS pre-approval for up to £3 million of investment. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is...

Bedford, UK, and Beijing, China – May 23rd 2020 Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, announced that on May 20th 2020, the UK Government launched an innovative new funding programme to support early-stage companies with a £250 million convertible loan matching fund, The Future Fund. The Future Fund is open to companies that: are incorporated in the UK; have raised at least £250,000 in equity investment from third-party investors in the last 5 years are not publicly listed were incorporated on or before 31 December 2019; and at least half of its...

Bedford, UK, April 3rd 2020 Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports that it has received notice of award of Hong Kong patent number 1252537, “Acaricides”. This patent protects the use of replicating biological agents for control of house dust mites, a key cause of asthma and other allergic conditions, and follows on from the award of European patent 3331366. Examination of applications proceeding from the underlying PCT application GB2016/052455 is proceeding in other jurisdictions. Dr. David Harper, Evolution’s CEO, said “this represents a key part of our strategy and highlights the...

Bedford, UK, March 18th 2020 Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports the appointment of Panda New Capital (PNC) and its partners as global financial advisors to the company. Evolution has been working with Panda New Capital (PNC) since late 2019 and has agreed to expand the roles of PNC and its partner companies from Asian markets to a global role. Dr. David Harper, Evolution’s CEO, said “we see expansion into Asia as a key priority for the company and we have found working with Panda New Capital to be highly productive....

Bedford, UK, June 7th, 2019 Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today received a letter of support from Asthma UK, the charity dedicated to improving the health and well-being of the 5.4 million people in the UK whose lives are affected by asthma. The letter was provided following a meeting with senior staff of the charity, and states: “Asthma UK welcomes your proposal, which seeks to establish a novel approach to remove triggers of asthma by targeting house dust mites through development of a biological control agent. People with asthma...

Bedford, UK, February 23rd, 2019 Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports that as a holder of the European Seal of Excellence for its work on house dust mite control, it has been selected to participate in the InvestEU Matchmaking event, to be held in Brussels, Belgium, on March 19th, 2019. The event involves discussions on sustainable finance and innovation, the Investment Plan for Europe, the InvestEU programme, and the Horizon 2020 and Horizon Europe programmes. After the discussions, attendees are invited to attend a dedicated matchmaking session with...

Bedford, UK, January 9th, 2019 Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports an interview with CEO Dr. David Harper, conducted by media company Proactive Investors during Biotech Showcase 2019. The interview covered the background to Evolution’s development of a novel, self-replicating control technology for house dust mites. Also covered were the recent granting of a European patent for this approach, and the company’s development plans. Dr. David Harper, Evolution’s CEO, said: “It is good to have the opportunity to speak to a wider audience about Evolution’s exciting developments in this...